Research programme: GlcNAc-TV inhibitors - InflazymeAlternative Names: GlcNAc-TV inhibitors research programme - Inflazyme
Latest Information Update: 30 Jul 2004
At a glance
- Originator Inflazyme Pharmaceuticals
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2004 No development reported - Preclinical for Cancer in Canada (PO)
- 17 Jun 2003 GLYCODesign has been acquired by Inflazyme Pharmaceuticals
- 16 Aug 2002 This programme is still in active development